Payment overview · 2025
General Payments
$31.28
2 reported records · 2 companies
Healthcare provider profile · identity verified
Henry Joseph Dupre, M.D.
Allopathic & Osteopathic Physicians|Emergency Medicine · VILLE PLATTE, LA · NPI 1811935935
Verified facts
What the public records show
CMS Open Payments records show Henry Joseph Dupre, M.D. received $31.28 in general payments during 2025 across 2 reported records.
TOLMAR, INC. accounted for 51.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $16.10 | 51.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.18 | 48.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $31.28 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 486 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 351 | 67 |
| Metformin Hcl Er | Metformin Hcl | 288 | 43 |
| Gabapentin | Gabapentin | 278 | 47 |
| Irbesartan | Irbesartan | 271 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 270 | 52 |
| Simvastatin | Simvastatin | 265 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 254 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 245 | 40 |
| Trazodone Hcl | Trazodone Hcl | 204 | 42 |
| Montelukast Sodium | Montelukast Sodium | 196 | 37 |
| Glimepiride | Glimepiride | 194 | 28 |
| Lisinopril | Lisinopril | 189 | 33 |
| Celecoxib | Celecoxib | 172 | 39 |
| Omeprazole | Omeprazole | 160 | 28 |
| Allopurinol | Allopurinol | 157 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 29 |
| Pregabalin | Pregabalin | 138 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 19 |
| Potassium Chloride | Potassium Chloride | 108 | 20 |
| Tramadol Hcl | Tramadol Hcl | 104 | 32 |
| Famotidine | Famotidine | 101 | 17 |
| Metformin Hcl | Metformin Hcl | 97 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 16 |
| Furosemide | Furosemide | 94 | 20 |
| Losartan Potassium | Losartan Potassium | 91 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 16 |
| Meloxicam | Meloxicam | 86 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 17 |
| Ezetimibe | Ezetimibe | 82 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 66 |
| Trulicity | Dulaglutide | 80 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 11 |
| Chlorthalidone | Chlorthalidone | 77 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 76 | 16 |
| Alprazolam | Alprazolam | 74 | 17 |
| Lorazepam | Lorazepam | 68 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | suppressed |
| Prednisone | Prednisone | 59 | 54 |
| Carvedilol | Carvedilol | 55 | 13 |
| Sertraline Hcl | Sertraline Hcl | 53 | suppressed |
| Naproxen | Naproxen | 52 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 14 |
| Clonidine Hcl | Clonidine Hcl | 49 | suppressed |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 11 |
| Alendronate Sodium | Alendronate Sodium | 46 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 46 | suppressed |
| Ozempic | Semaglutide | 46 | 11 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 40 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Eliquis | Apixaban | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Sucralfate | Sucralfate | 27 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 27 | 15 |
| Atenolol | Atenolol | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Trimethoprim | Trimethoprim | 23 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Olanzapine | Olanzapine | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 22 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Lactulose | Lactulose | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | 11 |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Tacrolimus | Tacrolimus | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $31.28 · 2 records | TOLMAR, INC. | JARDIANCE, JATENZO | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error